New Injectable Treatments for Parkinson’s Disease

Recent developments could significantly improve the lives of over 8 million individuals living with Parkinson’s disease. Researchers at the University of South Australia have created a long-acting injectable drug that could replace daily oral medications.

The Parkinson’s Foundation highlights that there are currently no comprehensive treatments for what is the second most common neurological disorder globally.

Interestingly, scientists at Stanford express surprise over potential new treatment options for Parkinson’s disease.

Currently, patients primarily rely on oral medications like levodopa and carbidopa, which aim to alleviate symptoms such as tremors, stiffness, and slower movements. However, for some, taking these pills can be quite challenging, especially for those who have trouble swallowing or maintaining consistent dosages. This inconsistency often leads to increased side effects and decreased effectiveness.

According to UNISA’s lead investigator, Professor Sanjay Garg, levodopa is considered the “gold standard” for treating Parkinson’s, but it’s short-lived, necessitating multiple daily doses.

The researchers experimented with injectable gel implants that incorporate biodegradable materials approved by the FDA, combined with pH-sensitive agents for steady drug release.

The injections can be administered through a single shot into the skin or muscle, meaning there’s no need for surgical implants and the discomfort is minimal.

Findings indicate that the gel can gradually release a significant proportion of essential Parkinson’s medications—90% of levodopa and 81% of carbohydrates—over the course of a week. These results were documented in the Journal of Drug Delivery and Translational Research.

Professor Garg remarked, “Transitioning from taking medications several times a day to just weekly injections marks a critical leap in Parkinson’s treatment. We’re not only bettering the methods of delivery; we’re enhancing our patients’ lives.”

The research team has conducted extensive laboratory tests verifying the system’s safety and effectiveness. Remarkably, the implants showed over 80% degradation within one week without causing significant toxicity in viability tests.

Deepa Nakmode, a doctoral student involved in the project, emphasized that the design is aimed at ensuring consistent plasma levels of both levodopa and other medications, thus mitigating risks that stem from fluctuating drug concentrations. She expresses immense satisfaction seeing years of rigorous research reach this promising stage.

Currently, the team is pursuing an Australian patent for their innovation.

This technology isn’t just limited to Parkinson’s; it holds potential for treating other chronic diseases like cancer, diabetes, and various neurological disorders that often require long-term medication management.

Plans for clinical trials are in the works, with hopes to see these injectables available in the market sometime soon.